



THE INTERCONNECTED WORLD OF BLOCKBUSTER PHARMACEUTICALS


How to read this infographic:




A look into how top-selling drugs are interconnected

This infographic visualizes the network of connections between 2017's top-selling pharmaceuticals. The most prevalent therapeutic area was Oncology—which made up 13 out of the top 50 drugs—followed by Neurology with 9. Biologics made up a sizeable portion of these blockbuster pharmaceuticals, with 19 of the displayed drugs having been submitted to the FDA under BLAs. The top-selling drug in 2017 was Humira, which brought in over \$18B, beating out the second-place Revlimid by over \$10B. These 50 pharmaceuticals alone accounted for over \$200B in revenue in 2017.







Sources: IQVIA Institute, PharmaCompass, National Code Directory, Healthline.gov, GSK, Eli Lilly, Amgen, Genentech, Biogen, Allergan, Teva, Novartis, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Regeneron Pharmaceuticals, Pfizer, Pharmacyclics, Janssen, Merck & Co, Sanofi-Aventis, Sunovion Pharmaceuticals, Novo Nordisk, Celgene, ViiV Healthcare, Shire, Astellas Pharma